LAERA, LETIZIA
 Distribuzione geografica
Continente #
NA - Nord America 773
EU - Europa 563
AS - Asia 98
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.437
Nazione #
US - Stati Uniti d'America 769
IE - Irlanda 146
GB - Regno Unito 135
CN - Cina 67
UA - Ucraina 59
SE - Svezia 56
IT - Italia 31
FR - Francia 30
DE - Germania 23
RU - Federazione Russa 17
LU - Lussemburgo 16
FI - Finlandia 15
ES - Italia 13
BE - Belgio 11
SG - Singapore 10
IN - India 8
CA - Canada 4
IR - Iran 4
TR - Turchia 4
CH - Svizzera 3
TH - Thailandia 3
AL - Albania 2
NO - Norvegia 2
CL - Cile 1
EU - Europa 1
GS - Georgia del Sud e Isole Sandwich Australi 1
JP - Giappone 1
KR - Corea 1
LV - Lettonia 1
PL - Polonia 1
RO - Romania 1
SI - Slovenia 1
Totale 1.437
Città #
Dublin 146
Fairfield 139
Southend 125
Woodbridge 76
Ann Arbor 67
Ashburn 54
Cambridge 54
Wilmington 54
Chandler 50
Jacksonville 48
Seattle 46
Houston 37
Princeton 24
Roodt-sur-Syre 14
Málaga 12
Nanjing 12
New York 12
Boardman 11
Brussels 11
San Mateo 11
Beijing 9
Siena 8
Jiaxing 7
Dallas 6
Helsinki 6
Nanchang 6
Singapore 6
Los Angeles 5
San Diego 5
Shenyang 5
Cagliari 4
Moscow 4
Shanghai 4
Taizhou 4
Hebei 3
Kunming 3
Monteroni Di Lecce 3
Redwood City 3
Venezia 3
Zanjan 3
Zhengzhou 3
Bangalore 2
Bangkok 2
Bari 2
Basel 2
Chennai 2
Dearborn 2
Düsseldorf 2
Istanbul 2
Jinan 2
London 2
Montreal 2
Munich 2
Ningbo 2
Oslo 2
San Carlos 2
Schifflange 2
Tirana 2
Adliswil 1
Bengaluru 1
Caccuri 1
Changsha 1
Chianciano Terme 1
Chicoutimi 1
Fuzhou 1
Guangzhou 1
Guidonia Montecelio 1
Gwanak-gu 1
Hefei 1
Iga 1
Indiana 1
Kashan 1
Kharkov 1
Kilburn 1
Lawrence 1
Mcallen 1
Milan 1
Norwalk 1
Nürnberg 1
Riga 1
Samut Sakhon 1
Santa Clara 1
Tappahannock 1
Targu 1
Tianjin 1
Toronto 1
Washington 1
Wood Green 1
Zgierz 1
Totale 1.168
Nome #
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 149
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 146
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 145
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 130
Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: A single-institution experience 120
null 103
null 98
null 96
null 88
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study 81
Metabolomics as predictive biomarker of response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) 80
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 54
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 40
null 39
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 38
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience. 36
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. 29
Totale 1.472
Categoria #
all - tutte 4.808
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.808


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020343 0 11 25 47 17 22 41 54 53 36 15 22
2020/2021240 7 26 16 29 10 28 11 36 17 32 20 8
2021/2022168 9 13 12 9 19 8 6 5 9 20 13 45
2022/2023204 14 17 34 27 17 41 18 8 11 12 0 5
2023/2024226 12 2 18 9 2 55 87 4 2 12 16 7
2024/202531 11 20 0 0 0 0 0 0 0 0 0 0
Totale 1.472